Uptake of Gilead's Yeztugo will be swift, analyst says after discussion with HIV doc
What kind of uptake can Gilead expect for its long-acting HIV prophylactic injection Yeztugo, which was approved last week by the FDA? A HIV physician, who shared her views with analysts from Mizuho Securities, expects that a “majority” of her 125 pre-exposure prophylaxis (PrEP) users will switch to Yeztugo within the next 12 months, according to an investor note recapping the discussion.
What kind of uptake can Gilead expect for its long-acting HIV prophylactic injection Yeztugo, which was approved last week by the FDA? A HIV physician, who shared her views with analysts from Mizuho Securities, expects that a “majority” of her 125 pre-exposure prophylaxis (PrEP) users will switch to Yeztugo within the next 12 months, according to an investor note recapping the discussion.
